You are here

Product Pipeline

OUR MEDICINES IN DEVELOPMENT

Our priority is researching and developing medicines and vaccines that will benefit patients around the world. We are committed to addressing unmet needs across a number of important therapeutic areas including, Oncology, Inflammation & Immunology, Vaccines, Internal Medicine and Rare Disease, with the goal of delivering innovative products to patients. 

Key Innovative Programs

Pipeline date and pdf

Pipeline Snapshot as of July 29, 2019

  • Discovery Projects
  • Phase 1
    35
  • Phase 2
    34
  • Phase 3
    23
  • Registration
    9
  • Total101
 
Compound Namesort descending
Indication
Phase
Submission Type
Compound Type
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Registration
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Anti PD-L1
Go to clinical trial
1st Line Renal Cell Carcinoma (Biologic) (Combo w/ Inlyta (axitinib)) (E.U.) Registration Product Enhancement Biologic
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Anti PD-L1
Go to clinical trial
1st Line Non-Small Cell Lung Cancer (Biologic) Phase 3 Product Enhancement Biologic
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Anti PD-L1
Go to clinical trial
1st Line Gastric Cancer (Biologic) Phase 3 Product Enhancement Biologic
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Anti PD-L1
Go to clinical trial
1st Line Urothelial Cancer (Biologic) Phase 3 Product Enhancement Biologic
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Anti PD-L1
Go to clinical trial
Combo w/ PF-04518600 (OX40) and PF-05082566 (anti-4-1BB/CD137) for Cancer (Biologic) Phase 1 Product Enhancement Biologic
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Anti PD-L1
Go to clinical trial
Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Biologic) Phase 3 Product Enhancement Biologic
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Anti PD-L1
Go to clinical trial
Combo w/ Talzenna (talazoparib) and binimetinib for Solid Tumors (Biologic) Phase 1 Product Enhancement Biologic
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Anti PD-L1
Go to clinical trial
Cancer (Biologic) Phase 1 Product Enhancement Biologic
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Anti PD-L1
Go to clinical trial
1st Line Merkel Cell Carcinoma (MCC) (Biologic) Phase 2 Product Enhancement Biologic
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Anti PD-L1
Go to clinical trial
Combo w/ PF-04518600 (OX40) for various solid tumors (Biologic) Phase 2 Product Enhancement Biologic
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Anti PD-L1
Go to clinical trial
Combo w/ PF-05082566 (anti-4-1BB/CD137) for various solid tumors (Biologic) Phase 2 Product Enhancement Biologic
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Anti PD-L1
Go to clinical trial
Combo w/ Talzenna (talazoparib) for Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors (Biologic) Phase 2 Product Enhancement Biologic
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Anti PD-L1
Go to clinical trial
Combo w/ Talzenna (talazoparib) for Solid Tumors with a BRCA or ATM defect (Biologic) Phase 2 Product Enhancement Biologic
Daurismo (glasdegib)
Therapeutic Area:
Oncology
Phase:Registration
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
SMO (smoothened) antagonist
Go to clinical trial
Combo w/ low-dose cytarabine (LDAC) for Acute Myeloid Leukemia (E.U.)
Project advanced
Registration New Molecular Entity Small Molecule
Daurismo (glasdegib)
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
SMO (smoothened) antagonist
Go to clinical trial
Myelodysplastic Syndrome Phase 2 Product Enhancement Small Molecule
Daurismo (glasdegib)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
SMO (smoothened) antagonist
Go to clinical trial
Combo w/azacytidine in Acute Myeloid Leukemia (ORPHAN - U.S., E.U.) Phase 3 Product Enhancement Small Molecule
Dekavil
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 2
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
IL-10
Go to clinical trial
Rheumatoid Arthritis (Biologic) Phase 2 New Molecular Entity Biologic
Dekavil
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 2
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
IL-10
Go to clinical trial
Inflammatory Bowel Disease (Biologic) Phase 2 Product Enhancement Biologic